Industry veteran at helm as clinical development advances
- 30 years of Industry expertise at Biogen and Merck
- Partner of Rosetta Capital
28th March 2020 – VasoDynamics Ltd, the pharmaceutical company developing therapies for common complexities in cancer treatment, today announces the appointment of founder, Dr Torsten Goesch, as Chairman, with immediate effect.
Ningfeng Fiona Li, CEO of VasoDynamics, said:
“Torsten brings extensive industry expertise and we are delighted he has stepped up to the helm of the Company at this pivotal stage in VasoDynamics development. As a young company, it is invaluable to have the guidance of an expert in our field of Torsten’s calibre as we navigate clinical development of our first three clinical stage products. We are passionate about helping cancer patients suffering from debilitating side-effects of cancer treatments and we believe that our products will not only improve their daily lives but also aid the impact of the cancer treatment itself.”
Dr. Goesch has a proven global commercial and asset manager/venture capitalist track record in building high-growth biotechnology and pharmaceutical companies. Currently, he is board member of Rosetta Capital in UK, Karolinska Development Invest in Sweden, Forward Pharma in Denmark (listed on NASDAQ in New York), Biosergen in Norway, EyeSense in Germany, Dilafor in Sweden, Dilaforette in Sweden, Promore Pharma in Sweden, Dr. Goesch Pharma in Singapore, Vistagen in Singapore and Zhangjiakou Biosergen Pharma in China. Previously Dr Goesch held senior leadership roles in Medicis, Biogen and Merck.
For enquiries, please contact:
|Ningfeng Fiona Li, CEO||+44 7969132263
|Mo Noonan, Mo PR Advisory||0787 6444977
Notes to Editors:
VasoDynamics is a UK pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy- and radiotherapy-induced mucositis, dermatitis and hair-loss. The Company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures to achieve the most effective and patient friendly protections to prevent severe side-effects during cancer treatments.